p27 ACTIVATES CDK4 AND BLOCKS PALBOCICLIB-MEDIATED CDK4 INHIBITION

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2020年 / 10卷 / 02期
关键词：
D O I：
10.1158/2159-8290.CD-RW2020-001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [31] TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML
    Uras, I.
    Valent, P.
    Sexl, V.
    HAEMATOLOGICA, 2017, 102 : 207 - 208
  • [32] Factors that limit delivery of Cdk4/6 inhibitor palbociclib to GBM
    Parrish, K.
    Pokorny, J.
    Mittapalli, R.
    Bakken, K.
    Sarkaria, J.
    Elmquist, W.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 86 - 86
  • [33] 首个CDK4/6抑制剂新药——Palbociclib
    康建磊
    王彦明
    临床药物治疗杂志, 2016, 14 (04) : 85 - 88
  • [34] Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells
    Patel, Priyank
    Tsiperson, Vladislav
    Gottesman, Susan R. S.
    Somma, Jonathan
    Blain, Stacy W.
    MOLECULAR CANCER RESEARCH, 2018, 16 (03) : 361 - 377
  • [35] Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis
    Duparc, Helene
    Muller, Delphine
    Antony-Debre, Ileana
    Marty, Caroline
    Debili, Najet
    Villeval, Jean-Luc
    Plo, Isabelle
    Vainchenker, William
    Gilles, Laure
    Raslova, Hana
    BLOOD, 2020, 136
  • [36] Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
    Guillaume, Zoe
    Medioni, Jacques
    Lillo-Lelouet, Agnes
    Marret, Gregoire
    Oudard, Stephane
    Simonaggio, Audrey
    CLINICAL BREAST CANCER, 2020, 20 (02) : E192 - E195
  • [37] Inducible deletion of CDK4 and CDK6-deciphering CDK4/6 inhibitor effects in the hematopoietic system
    Maurer, Barbara
    Brandstoetter, Tania
    Kollmann, Sebastian
    Sexl, Veronika
    Prchal-Murphy, Michaela
    HAEMATOLOGICA, 2021, 106 (10) : 2624 - 2632
  • [38] Application of CDK4/6 inhibition therapies to PDACs
    Zhang, Yuanyuan
    CANCER SCIENCE, 2023, 114 : 1937 - 1937
  • [39] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [40] Response and resistance to CDK2 and CDK4/6 inhibition in GIST
    Schaefer, Inga-Marie
    Lundberg, Meijun Z.
    Hemming, Matthew L.
    Saka, Sinem K.
    Serrata, Matthew P.
    Goldaracena, Isabel
    Liu, Ninning
    Yin, Peng
    Paulo, Joao A.
    Gygi, Steven
    Demetri, George D.
    Sicinska, Ewa
    Marino-Enriquez, Adrian
    Hornick, Jason L.
    Raut, Chandrajit P.
    Ou, Wen-Bin
    Fletcher, Jonathan A.
    CANCER RESEARCH, 2022, 82 (12)
12345